ICU Medical Inc expected to post earnings of $1.19 a share - Earnings Preview

ICU Medical

23/02/2024 21:25

* ICU Medical Inc  ICUI.OQ   ICUI.O  is expected to show a
fall in
quarterly revenue when it reports  results on February 27 for
the period ending December 31 2023
    * The San Clemente California-based  company is expected to
report
a 2.6% decrease in revenue to $563.025 million from $578.01
million a year ago, according to the mean estimate from 4
analysts, based on LSEG data. (Revenue majority Basis is on
Total Revenue(Non GAAP))
    * ​LSEG's mean analyst estimate for ICU Medical Inc is for
earnings of $1.19 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for ICU Medical
Inc
is $116.00​, above​ its last closing price of $102.95. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  1.42        1.39       1.57      Beat    13.4
 Jun. 30 2023  1.60        1.60       1.88      Beat    17.5
 Mar. 31 2023  1.44        1.43       1.74      Beat    22​
 Dec. 31 2022  1.60        1.56       1.60      Beat    2.6
 ​​Sep.        1.48        1.46       1.75      Beat    19.6
 30 2022                                                
 Jun. 30 2022  1.65        1.66       1.37      Missed  -17.5​
 Mar. 31 2022  1.78        1.78       1.82      Beat    2.1
 Dec. 31 2021  1.65        1.64       1.82      Beat    10.8
 This summary was machine generated February 23 at 21:25 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)